» Articles » PMID: 20358022

Eosinophil Survival and Apoptosis in Health and Disease

Overview
Date 2010 Apr 2
PMID 20358022
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Eosinophilia is common feature of many disorders, including allergic diseases. There are many factors that influence the production, migration, survival and death of the eosinophil. Apoptosis is the most common form of physiological cell death and a necessary process to maintain but limit cell numbers in humans and other species. It has been directly demonstrated that eosinophil apoptosis is delayed in allergic inflammatory sites, and that this mechanism contributes to the expansion of eosinophil numbers within tissues. Among the proteins known to influence hematopoiesis and survival, expression of the cytokine interleukin-5 appears to be uniquely important and specific for eosinophils. In contrast, eosinophil death can result from withdrawal of survival factors, but also by activation of pro-apoptotic pathways via death factors. Recent observations suggest a role for cell surface death receptors and mitochondria in facilitating eosinophil apoptosis, although the mechanisms that trigger each of these death pathways remain incompletely delineated. Ultimately, the control of eosinophil apoptosis may someday become another therapeutic strategy for treating allergic diseases and other eosinophil-associated disorders.

Citing Articles

Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.

DAiuto V, Mormile I, Granata F, Romano A, Della Casa F, Mignogna G Int J Mol Sci. 2025; 26(4).

PMID: 40004192 PMC: 11855446. DOI: 10.3390/ijms26041729.


Inotodiol Attenuates Mucosal Inflammation in a Mouse Model of Eosinophilic Chronic Rhinosinusitis.

Chung J, Im S, Park S, Heo D, Sung H, Ohm D Allergy Asthma Immunol Res. 2025; 17(1):77-93.

PMID: 39895604 PMC: 11791372. DOI: 10.4168/aair.2025.17.1.77.


Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma.

Menzella F, Marchi M, Caminati M, Romagnoli M, Micheletto C, Bonato M J Clin Med. 2025; 14(1.

PMID: 39797273 PMC: 11722057. DOI: 10.3390/jcm14010191.


Evidence for a Role of the Long Non-Coding RNA ITGB2-AS1 in Eosinophil Differentiation and Functions.

Fettrelet T, Hosseini A, Wyss J, Boros-Majewska J, Stojkov D, Yousefi S Cells. 2024; 13(23).

PMID: 39682685 PMC: 11640120. DOI: 10.3390/cells13231936.


Phenotypic Shift of an Inflammatory Eosinophil Subset into a Steady-State Resident Phenotype after 2 Years of Vaccination against IL-5 in Equine Insect Bite Hypersensitivity.

Schwarz E, Jebbawi F, Keller G, Rhiner T, Fricker A, Waldern N Vet Sci. 2024; 11(10).

PMID: 39453068 PMC: 11512288. DOI: 10.3390/vetsci11100476.


References
1.
Straumann A, Kristl J, Conus S, Vassina E, Spichtin H, Beglinger C . Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. Inflamm Bowel Dis. 2005; 11(8):720-6. DOI: 10.1097/01.mib.0000172557.39767.53. View

2.
Mishra A, Hogan S, Lee J, Foster P, Rothenberg M . Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest. 1999; 103(12):1719-27. PMC: 408388. DOI: 10.1172/JCI6560. View

3.
Geijsen N, Koenderman L, Coffer P . Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev. 2001; 12(1):19-25. DOI: 10.1016/s1359-6101(00)00019-8. View

4.
von Gunten S, Vogel M, Schaub A, Stadler B, Miescher S, Crocker P . Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol. 2007; 119(4):1005-11. DOI: 10.1016/j.jaci.2007.01.023. View

5.
Denburg J, Sehmi R, Saito H, Inman M, OByrne P . Systemic aspects of allergic disease: bone marrow responses. J Allergy Clin Immunol. 2000; 106(5 Suppl):S242-6. DOI: 10.1067/mai.2000.110156. View